Endothelial-independent prevention of high blood pressure in L-NAME-treated rats by angiotensin II type I receptor antisense gene therapy

Experimental Physiology

Volumn 88, Issue 4, 2003, Pages 467-473

  Reaves, Phyllis Y ^a   Beck, Caren R ^a,b   Wang, Hong Wei ^a   Raizada, Mohan K ^a   Katovich, Michael J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; DRINKING WATER; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BODY WEIGHT; BOLUS INJECTION; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM INJURY; GENE EXPRESSION; GENE THERAPY; HEART HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; NEWBORN; NONHUMAN; RAT; RAT STRAIN; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENE; VASODILATATION; VIRAL GENE THERAPY; VIRUS PARTICLE;

EID: 0038784716     PISSN: 09580670     EISSN: None     Source Type: Journal    
DOI: 10.1113/eph8802579     Document Type: Review

References (48)

1. Arnal JF, el Amrani AI, Chatelliwe G, Menard J & Michel JB (1993). Cardiac weight in hypertension induced by nitric oxide synthetase blockade. Hypertension 22, 380-387.
2. Bergamaschi CT, Biancardi VC, Lopes OU & Campos RY (2002). Effect of angiotensin blockade in the rostral ventrolateral medulla on maintenance of hypertension induced by chronic L-NAME treatment. Brain Res 927, 195-199.
3. Bernatova I, Pechanova O, Pelouch V & Simko F (2000). Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 32, 177-185.
4. Cachofeiro V, Maeso R, Munoz-Garcia R & Lahera V (1996). The potential role of nitric oxide in angiotensin II- receptor blockade. Blood Press Suppl 2, 29-35.
5. Chen LM, Chao L & Chao J (1997). Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther 8, 341-347.
6. De Gracia MC, Osuna A, O'Valle F, Del Moral RG, Wangensteen R, Del Rio CG & Vargas F (2000). Deoxycorticosterone suppresses the effects of losartan in nitric oxide-deficient hypertensive rats. J Am Soc Nephrol 11, 1995-2000.
7. 1 receptor antagonism reduces endothelial dysfunction and intimal thickness in atherosclerotic rabbits. Hypertension 34, 969-975.
8. Eshima K, Hirooka Y, Shigematsu H, Matsuo I, Koike G, Sakai K & Takeshita A (2000). Angiotensin in the nucleus tractus solitarius contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 36, 259-263.
9. Fitzsimons JT (1998). Angiotensin, thirst, and sodium appetite. Physiol Rev 78, 583-686.
10. Inagami T (1994). The renin-angiotensin system. Essays Biochem 28, 147-164.
11. Iyer SN & Katovich MJ (1996). Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance. Clin Exp Hypertens 18, 227-242.
12. Iyer SN, Lu D, Katovich MJ & Raizada MK (1996). Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci U S A 93, 9960-9965.
13. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H & Takeshita A (1998). Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthase in rats. Circ Res 83, 743-751.
14. Kimura B, Mohuczy D, Tang X & Phillips MI (2001). Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension 37, 376-380.
15. K-Laflamme A, Oster L, Cardinal R & de Champlain J (1998). Role of NO and angiotensin in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. Can J Physiol Pharmacol 76, 665-675.
16. Kobayashi N, Hara K, Watanabe S, Higashi T & Matsuoka H (2000). Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Am J Hypertens 13, 199-207.
17. Kucuk M, Kaya M, Kalayci R, Cimen V, Kudat H, Arican N, Elmas I & Korkut F (2002). Effects of losartan on the blood brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats. Life Sci 71, 937-946.
18. Kung CF, Moreau P, Takase H & Luscher TF (1995). L-NAME hypertension alters endothelial and smooth muscle function in rat aorta: prevention by trandolapril and verapamil. Hypertension 26, 744-751.
19. Lee J, Kim S, Oh Y, Ryu SY & Kim SW (2002). Upregulation of vascular renin-angiotensin and endothelin systems in rats inhibited of nitric oxide synthesis. Pharmacol Res 46, 383-387.
20. Lerch M, Teuscher AU, Beissner P, Schneider M, Shaw SG & Weidmann P (1998). Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 31, 576-580.
21. Lu D, Raizada MK, Iyer S, Reaves P, Yang H & Katovich MJ (1997). Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30, 363-370.
22. Makino N, Sugano M, Ohtsuka S, Sawada S & Hata T (1999). Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc Res 44, 543-548.
23. Mancini GB (1998). Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med 105, 40S-47S.
24. Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada MK & Gelband CH (1998). Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci U S A 95, 2664-2669.
25. Matsubara BB, Matsubara LS, Zornoff LA, Franco M & Janicki JS (1998). Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 93, 173-181.
26. G-nitro L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol 28, 142-148.
27. Moreau P, Takase H, d'Uscio LV & Luscher TF (1998). Effect of chronic nitric oxide deficiency on angiotensin II-induced hypertrophy of rat basilar artery. Stroke 29, 1031-1036.
28. Moreau P, Takase K, Kung CF, Shaw S & Luscher TF (1997). Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 29, 763-769.
29. ω-nitro L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 37, 1262-1267.
30. Pachori AS, Huentelman MJ, Francis SC, Gelband CH, Katovich MJ & Raizada MK (2001). The future of hypertension therapy: sense, antisense or nonsense? Hypertension 37, 357-364.
31. 1R-AS gene therapy. Hypertension 39, 969-675.
32. 1 receptor antisense. Circ Res 86, 1167-1172.
33. Parmley WW (1998). Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med 105, 27S-31S.
34. Qiu C, Engels K & Baylis C (1994). Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol 35, R1470-1476.
35. 1 receptor antisense gene therapy in hypertensive rat offspring. Circ Res 85, e44-50.
36. Reaves PY, Wang H-W, Katovich MJ, Gelband CH & Raizada MK (2000). Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA. Methods 22, 211-218.
37. Rodrigo E, Masero R, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachofeiro V & Lahera V (1997). Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens 15, 613-618.
38. 1 receptor antagonists on cardiac remodeling induced by inhibition on NO synthesis in rats. Hypertension 38, 404-411.
39. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE & Rosengart TK (2000). Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel survey. Circulation 102, E73-86.
40. SoRelle R (2000). AHA and federal agencies agree to cooperate to attack heart disease and stroke. Circulation 103, E9015-E9016.
41. G-nitro-L-arginine methyl ester-induced hypertension and natriuretic peptide gene expression: inhibition by angiotensin II type 1 receptor antagonism. J Cardiovasc Pharmacol 40, 478-486.
42. Takase H, Moreau P, Kung CF, Nava E & Luscher TF (1996). Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: effect of verapamil and trandolapril. Hypertension 27, 25-31.
43. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K & Takeshita A (1997a). Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30, 1621-1627.
44. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K & Takeshita A (1997b). Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structure changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99, 278-287.
45. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DL, Lee RJ, Wexler RR, Saye JA & Smith RD (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45, 205-251.
46. Usui M, Ichiki T, Katoh M, Egashira K & Takeshita A (1998). Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 32, 527-533.
47. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR & Weaber B (1995). Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 268, H2267-2273.
48. Zimmerman BG (1981). Adrenergic facilitation by angiotensin: does it serve a physiological function. Clin Sci 60, 343-348.